Mikhail Yu. Prokudin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mikhail Yu. Prokudin has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Igor’ Vyacheslavovich Litvinenko
S.M. Kirov Military Medical Academy
8 shared publications - Boris V. Martynov
Kirov Military Medical Academy
6 shared publications - Dmitrij Vladimirovich Svistov
Kirov Military Medical Academy
6 shared publications - Olga A. Klitsenko
Mechnikov North-West State Medical University
5 shared publications - Emma Yu. Klimenkova
Medical Military Academy
4 shared publications - Miroslav Mihailovich Odinak
Kirov Military Medical Academy
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2620
Proton Magnetic Resonance Spectroscopy in the Assessment of Metabolic Changes in Brain Gliomas and the Perifocal Zone: A Pilot Study
Введение. Глиомы высокой степени злокачественности (Grade 3–4 по классификации ВОЗ, 2021) представляют собой наиболее инфильтративные опухоли головного мозга. Распространенность данных опухолей в развитых странах составляет около 5,9 случая на каждые 100 тыс. человек, при этом показатель летальности составляет 4,0 случая на 100 тыс. населения [1]. Несмотря на развитие нейрохирургии, совершенствование протоколов химиотерапии и лучевой терапии, медиана выживаемости пациентов с глиобластомой остается низкой — около 14-16 мес. [2-5]. Цель. Проведение пилотного исследования по оценке метаболических изменений в опухоли и перифокальной зоне высокозлокачественных глиом с возможностью включения в диагностический протокол данных протонной магнитно-резонансной спектроскопии (¹H-MRS). Материалы и методы. Проведено проспективное пилотное исследование пациентов с подозрением на глиальные опухоли головного мозга, в группу входили мужчины и женщины в возрасте от 18 до 70 лет, позиционирование вокселя для спектроскопии осуществлялось на контрольных МР-изображениях с использованием матрицы многовоксельной спектроскопии. Область интереса выбиралась непосредственно в пределах этой матрицы. Результаты. Проведение ¹H-MRS-исследования у 27 пациентов с опухолями глиального ряда позволило выявить метаболические изменения в опухолевом узле и перифокальной зоне по сравнению с интактной тканью головного мозга. Сравнение метаболических параметров между гистологическими подтипами показало, что у глиобластом (IDH-wt) значение Cho/NAA было выше на 35-50 %, чем при IDH-мутантных астроцитомах (р < 0,05). Выводы. Проведенное исследование подтвердило, что ¹H-MRS является высокоинформативной методикой для оценки метаболических изменений при глиомах высокой степени злокачественности.
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2620
Open AccessProton Magnetic Resonance Spectroscopy in the Assessment of Metabolic Changes in Brain Gliomas and the Perifocal Zone: A Pilot Study
Введение. Глиомы высокой степени злокачественности (Grade 3–4 по классификации ВОЗ, 2021) представляют собой наиболее инфильтративные опухоли головного мозга. Распространенность данных опухолей в развитых странах составляет около 5,9 случая на каждые 100 тыс. человек, при этом показатель летальности составляет 4,0 случая на 100 тыс. населения [1]. Несмотря на развитие нейрохирургии, совершенствование протоколов химиотерапии и лучевой терапии, медиана выживаемости пациентов с глиобластомой остается низкой — около 14-16 мес. [2-5]. Цель. Проведение пилотного исследования по оценке метаболических изменений в опухоли и перифокальной зоне высокозлокачественных глиом с возможностью включения в диагностический протокол данных протонной магнитно-резонансной спектроскопии (¹H-MRS). Материалы и методы. Проведено проспективное пилотное исследование пациентов с подозрением на глиальные опухоли головного мозга, в группу входили мужчины и женщины в возрасте от 18 до 70 лет, позиционирование вокселя для спектроскопии осуществлялось на контрольных МР-изображениях с использованием матрицы многовоксельной спектроскопии. Область интереса выбиралась непосредственно в пределах этой матрицы. Результаты. Проведение ¹H-MRS-исследования у 27 пациентов с опухолями глиального ряда позволило выявить метаболические изменения в опухолевом узле и перифокальной зоне по сравнению с интактной тканью головного мозга. Сравнение метаболических параметров между гистологическими подтипами показало, что у глиобластом (IDH-wt) значение Cho/NAA было выше на 35-50 %, чем при IDH-мутантных астроцитомах (р < 0,05). Выводы. Проведенное исследование подтвердило, что ¹H-MRS является высокоинформативной методикой для оценки метаболических изменений при глиомах высокой степени злокачественности.
- 7 November 2025
- Published by ECO-Vector LLC (Publications) in Russian Military Medical Academy Reports
- Vol. 44 (4) , 381-394
Post-traumatic epilepsy as a consequence of gunshot penetrating head injury with intracranial metallic foreign body: epidemiology, prevention, and treatment algorithms
BACKGROUND: The growing number of armed conflicts worldwide is leading to an increase in patients with combat-related traumatic brain injury, including those with intracranial metallic foreign bodies. Acute symptomatic post-traumatic epileptic seizures constitute a cause of secondary brain injury, whereas post-traumatic epilepsy may become the only disabling and quality-of-life-limiting consequence of head trauma, requiring prolonged antiseizure therapy. AIM: This work aimed to investigate epidemiological features, diagnostic characteristics of epileptic seizures, and post-traumatic epilepsy in military personnel with intracranial metallic foreign bodies, and to evaluate algorithms for preventive antiseizure medication and treatment of post-traumatic epilepsy. METHODS: A prospective study included 93 military personnel who sustained a gunshot penetrating head injury with an intracranial metallic foreign body. Patients were divided into two groups: group 1 (n = 63) with intracranial metallic foreign body retained; group 2 (n = 30) with intracranial metallic foreign body surgically removed within 4 months post-injury. To assess different approaches to preventive antiseizure therapy, both groups were subdivided into two subgroups: patients receiving prophylactic antiseizure medications (1a and 2a); patients without prophylactic antiseizure treatment (1b and 2b). RESULTS: Post-traumatic epilepsy was diagnosed in 18 of 93 patients (19.4%). In group 1, a total of 13 patients (20.6%) developed epilepsy: 8 of 27 (29.6%) in subgroup 1a and 5 of 36 (13.9%) in subgroup 1b. In group 2, epilepsy occurred in 5 patients (16.7%): 4 of 16 (25%) in subgroup 2a and 1 of 14 (7.1%) in subgroup 2b. Among group 1 patients with post-traumatic epilepsy (n = 13), epileptiform activity on electroencephalogram was detected in 7 patients (53.8%), and paroxysmal slow-wave activity in 3 patients (23.1%). In subgroups, epileptiform activity was detected in 6 patients (22.2%) and paroxysmal slow-wave activity in 5 patients (18.5%) in 1a; and in 5 patients (13.9%) and 4 patients (11.1%) in 1b, respectively. Among subgroup 2a patients, epileptiform activity or paroxysmal slow-wave activity were detected in 8 of 16 patients (50%), with 4 patients demonstrating either pattern. In subgroup 2b, 13 of 14 patients demonstrated no epileptiform or paroxysmal slow-wave activity on electroencephalogram. CONCLUSION: An intracranial metallic foreign body is a significant risk factor for post-traumatic epilepsy. The use of antiseizure medications for prophylaxis of epileptic seizures in this group of military personnel is not recommended. Paroxysmal slow-wave activity on electroencephalogram serves as a predictor of post-traumatic epilepsy and may guide preventive and therapeutic decision-making algorithms.
- 7 November 2025
- Published by ECO-Vector LLC (Publications) in Russian Military Medical Academy Reports
- Vol. 44 (4) , 381-394
Post-traumatic epilepsy as a consequence of gunshot penetrating head injury with intracranial metallic foreign body: epidemiology, prevention, and treatment algorithms
BACKGROUND: The growing number of armed conflicts worldwide is leading to an increase in patients with combat-related traumatic brain injury, including those with intracranial metallic foreign bodies. Acute symptomatic post-traumatic epileptic seizures constitute a cause of secondary brain injury, whereas post-traumatic epilepsy may become the only disabling and quality-of-life-limiting consequence of head trauma, requiring prolonged antiseizure therapy. AIM: This work aimed to investigate epidemiological features, diagnostic characteristics of epileptic seizures, and post-traumatic epilepsy in military personnel with intracranial metallic foreign bodies, and to evaluate algorithms for preventive antiseizure medication and treatment of post-traumatic epilepsy. METHODS: A prospective study included 93 military personnel who sustained a gunshot penetrating head injury with an intracranial metallic foreign body. Patients were divided into two groups: group 1 (n = 63) with intracranial metallic foreign body retained; group 2 (n = 30) with intracranial metallic foreign body surgically removed within 4 months post-injury. To assess different approaches to preventive antiseizure therapy, both groups were subdivided into two subgroups: patients receiving prophylactic antiseizure medications (1a and 2a); patients without prophylactic antiseizure treatment (1b and 2b). RESULTS: Post-traumatic epilepsy was diagnosed in 18 of 93 patients (19.4%). In group 1, a total of 13 patients (20.6%) developed epilepsy: 8 of 27 (29.6%) in subgroup 1a and 5 of 36 (13.9%) in subgroup 1b. In group 2, epilepsy occurred in 5 patients (16.7%): 4 of 16 (25%) in subgroup 2a and 1 of 14 (7.1%) in subgroup 2b. Among group 1 patients with post-traumatic epilepsy (n = 13), epileptiform activity on electroencephalogram was detected in 7 patients (53.8%), and paroxysmal slow-wave activity in 3 patients (23.1%). In subgroups, epileptiform activity was detected in 6 patients (22.2%) and paroxysmal slow-wave activity in 5 patients (18.5%) in 1a; and in 5 patients (13.9%) and 4 patients (11.1%) in 1b, respectively. Among subgroup 2a patients, epileptiform activity or paroxysmal slow-wave activity were detected in 8 of 16 patients (50%), with 4 patients demonstrating either pattern. In subgroup 2b, 13 of 14 patients demonstrated no epileptiform or paroxysmal slow-wave activity on electroencephalogram. CONCLUSION: An intracranial metallic foreign body is a significant risk factor for post-traumatic epilepsy. The use of antiseizure medications for prophylaxis of epileptic seizures in this group of military personnel is not recommended. Paroxysmal slow-wave activity on electroencephalogram serves as a predictor of post-traumatic epilepsy and may guide preventive and therapeutic decision-making algorithms.
- Open Access
- 23 July 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 1,p. 72-76
Epileptic seizure as a mask of paroxysmal atrial fibrillation
Transient loss of consciousness is frequently encountered in the practice of physicians of various specialties. These conditions can be caused by multiple factors that can be divided into two major groups: traumatic and non-traumatic. Non-trauma-related loss of consciousness includes epileptic seizures and syncopal states. Among the latter, it is important to identify cardiogenic syncope as the most significant and common. They can be associated with various structural cardiac pathologies, as well as rhythm and conduction disorders. However, when encountering cardiogenic syncope in a patient with a previously established diagnosis of epilepsy, the physician may face a challenging diagnostic situation. The previous diagnosis typically initially leads to the assumption of another epileptic seizure. The article systematizes and analyzes data from domestic and foreign literature on the differential diagnosis of cardiogenic syncope and epileptic seizures. A clinical observation of a patient with a history of epilepsy and transient loss of consciousness due to paroxysmal atrial fibrillation is presented. Knowledge of the clinical manifestation features of these conditions can help specialists in making the correct diagnosis, as well as prescribing necessary therapy and preventing complications of atrial fibrillation.
- 23 July 2025
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 1,p. 72-76
Open AccessEpileptic seizure as a mask of paroxysmal atrial fibrillation
Transient loss of consciousness is frequently encountered in the practice of physicians of various specialties. These conditions can be caused by multiple factors that can be divided into two major groups: traumatic and non-traumatic. Non-trauma-related loss of consciousness includes epileptic seizures and syncopal states. Among the latter, it is important to identify cardiogenic syncope as the most significant and common. They can be associated with various structural cardiac pathologies, as well as rhythm and conduction disorders. However, when encountering cardiogenic syncope in a patient with a previously established diagnosis of epilepsy, the physician may face a challenging diagnostic situation. The previous diagnosis typically initially leads to the assumption of another epileptic seizure. The article systematizes and analyzes data from domestic and foreign literature on the differential diagnosis of cardiogenic syncope and epileptic seizures. A clinical observation of a patient with a history of epilepsy and transient loss of consciousness due to paroxysmal atrial fibrillation is presented. Knowledge of the clinical manifestation features of these conditions can help specialists in making the correct diagnosis, as well as prescribing necessary therapy and preventing complications of atrial fibrillation.
- Open Access
- 8 December 2024
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 43 (4) , 401-409
Clinical prognostic factors in patients with diffuse gliomas of the brain
BACKGROUND: Diffuse gliomas of the brain represent a heterogeneous group, which differs in age of the disease onset, histologic characteristics, tumor grade, molecular genetic markers and prognosis. AIM: of the present study is to identify the factors, which affect the duration of the relapse-free period and life expectancy in patients with diffuse brain gliomas, based on a comprehensive analysis of clinical syndromes and symptoms. MATERIALS AND METHODS: The study was carried out at the Departments of Neurosurgery and Nerve Diseases of the S.M. Kirov Military Medical Academy (Saint Petersburg, Russia). It included 390 in-patients with diffuse brain gliomas who underwent treatment over the periods of 2014–2022 and 2004–2006. Age at time of diagnosis was 45.26 ± 15.72 years old. The study included 218 (55.9%) male and 172 (44.1%) female patients. It was a single-centre prospective study. RESULTS: of the author’s research. Favourable demographic factors include the age range of 18–39 (relapse-free period duration p 0.01, life expectancy p 0.001) and female sex (relapse-free period p = 0.02, life expectancy p = 0.03). Prognostically favourable clinical manifestations include epileptic seizures before surgery (relapse-free period p 0.01, life expectancy p 0.02); unfavourable clinical manifestations are pyramidal syndrome (relapse-free period p 0.01, life expectancy p 0.001), sensitive disorders (relapse-free period p = 0.045–0.12, life expectancy p = 0.09–0.17), speech pathology (relapse-free period p 0.02, life expectancy p = 0.02–0.12) and cerebellar syndrome (relapse-free period p 0.02, life expectancy p 0.001). Clinical signs such as headache, nausea and vomiting, asthenia, diffuse neurological symptoms, craniocerebral nerve involvement and visual impairment do not affect (p 0.05) the outcomes of the patients with diffuse brain gliomas. CONCLUSION: Thus, favourable demographic prognostic factors include female sex and age range of 18–39, favourable clinical prognostic factors include epileptic seizures before surgery. Unfavourable clinical prognostic factors include presence of motor, sensory disorders, speech impairment and cerebellar syndrome.
- 8 December 2024
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 43 (4) , 401-409
Open AccessClinical prognostic factors in patients with diffuse gliomas of the brain
BACKGROUND: Diffuse gliomas of the brain represent a heterogeneous group, which differs in age of the disease onset, histologic characteristics, tumor grade, molecular genetic markers and prognosis. AIM: of the present study is to identify the factors, which affect the duration of the relapse-free period and life expectancy in patients with diffuse brain gliomas, based on a comprehensive analysis of clinical syndromes and symptoms. MATERIALS AND METHODS: The study was carried out at the Departments of Neurosurgery and Nerve Diseases of the S.M. Kirov Military Medical Academy (Saint Petersburg, Russia). It included 390 in-patients with diffuse brain gliomas who underwent treatment over the periods of 2014–2022 and 2004–2006. Age at time of diagnosis was 45.26 ± 15.72 years old. The study included 218 (55.9%) male and 172 (44.1%) female patients. It was a single-centre prospective study. RESULTS: of the author’s research. Favourable demographic factors include the age range of 18–39 (relapse-free period duration p 0.01, life expectancy p 0.001) and female sex (relapse-free period p = 0.02, life expectancy p = 0.03). Prognostically favourable clinical manifestations include epileptic seizures before surgery (relapse-free period p 0.01, life expectancy p 0.02); unfavourable clinical manifestations are pyramidal syndrome (relapse-free period p 0.01, life expectancy p 0.001), sensitive disorders (relapse-free period p = 0.045–0.12, life expectancy p = 0.09–0.17), speech pathology (relapse-free period p 0.02, life expectancy p = 0.02–0.12) and cerebellar syndrome (relapse-free period p 0.02, life expectancy p 0.001). Clinical signs such as headache, nausea and vomiting, asthenia, diffuse neurological symptoms, craniocerebral nerve involvement and visual impairment do not affect (p 0.05) the outcomes of the patients with diffuse brain gliomas. CONCLUSION: Thus, favourable demographic prognostic factors include female sex and age range of 18–39, favourable clinical prognostic factors include epileptic seizures before surgery. Unfavourable clinical prognostic factors include presence of motor, sensory disorders, speech impairment and cerebellar syndrome.
- 24 July 2024
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 29 (3) , 49-57
Outcomes of epilepsy surgery in patients with diffuse gliomas of the brain
The objectives of surgical treatment of patients with diff use brain gliomas include achieving control over epileptic seizures and improving quality of life, in addition to prolonging relapse-free period and life duration. The aim of the research is to study the factors that determine the eff ectiveness of epilepsy surgery in patients with diffuse brain gliomas. Material and methods. The study group comprised 104 patients with diff use brain gliomas, aged 41.21 ± 14.74. Results of author’s research. Clinical, neuroimaging and morphological factors were studied. Of the studied group of 104 patients with diffuse brain gliomas who had been diagnosed with epilepsy prior to surgery, the remission of 6 months after surgery was achieved in 58 (55.77 %) patients and of 12 months in 55 (52.88 %) patients. The development of acute symptomatic epileptic seizures (p = 0.68067) and acute symptomatic status epilepticus (p = 0.41626) in post-operative period do not determine the outcomes of epilepsy surgery. Neither the histological subtype of the diffuse brain gliomas, nor the molecular-genetic factor (IDH1/2 mutation, 1p/19q codeletion) determines the outcomes of epilepsy surgery in this patient category. The group of antiepileptic medications or the medication regimen (monotherapy, two-drug therapy) also does not determine the surgery outcomes. The factors that determine a favorable outcome of surgical treatment for epilepsy in patients with diff use brain gliomas are complete tumor removal and involvement of brain commissures after magnetic resonance imaging before surgery. Conclusion. The effectiveness of epilepsy surgery is determined by the radical removal of the diff use brain glioma, thereby eliminating the glutamate-mediated mechanisms of epileptogenesis.
- 24 July 2024
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 29 (3) , 49-57
Outcomes of epilepsy surgery in patients with diffuse gliomas of the brain
The objectives of surgical treatment of patients with diff use brain gliomas include achieving control over epileptic seizures and improving quality of life, in addition to prolonging relapse-free period and life duration. The aim of the research is to study the factors that determine the eff ectiveness of epilepsy surgery in patients with diffuse brain gliomas. Material and methods. The study group comprised 104 patients with diff use brain gliomas, aged 41.21 ± 14.74. Results of author’s research. Clinical, neuroimaging and morphological factors were studied. Of the studied group of 104 patients with diffuse brain gliomas who had been diagnosed with epilepsy prior to surgery, the remission of 6 months after surgery was achieved in 58 (55.77 %) patients and of 12 months in 55 (52.88 %) patients. The development of acute symptomatic epileptic seizures (p = 0.68067) and acute symptomatic status epilepticus (p = 0.41626) in post-operative period do not determine the outcomes of epilepsy surgery. Neither the histological subtype of the diffuse brain gliomas, nor the molecular-genetic factor (IDH1/2 mutation, 1p/19q codeletion) determines the outcomes of epilepsy surgery in this patient category. The group of antiepileptic medications or the medication regimen (monotherapy, two-drug therapy) also does not determine the surgery outcomes. The factors that determine a favorable outcome of surgical treatment for epilepsy in patients with diff use brain gliomas are complete tumor removal and involvement of brain commissures after magnetic resonance imaging before surgery. Conclusion. The effectiveness of epilepsy surgery is determined by the radical removal of the diff use brain glioma, thereby eliminating the glutamate-mediated mechanisms of epileptogenesis.
- 22 February 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 2,p. 213-224
Quality of life indicators in patients with diffuse brain gliomas
The incidence of primary brain tumors is increasing worldwide. When assessing the treatment delivered to patients with brain gliomas, their quality of life (QOL) is an essential criterion for consideration. It is necessary to search for and specify the factors, which determine the QOL changes in patients with brain tumors. The QOL indicators for patients with brain gliomas were assessed in terms of the following factors: clinical (presence of epileptic seizures, seizures type and frequency, antiepileptic drug treatment, presence of speech disorders and pareses), demographic (sex), age of diagnosis, social (level of education, employment, marital status), molecular-genetic (presence of IDH1/2 mutation, 1p/19q codeletion), and morphological (malignancy degree, tumor histological characteristics). The QOL of 48 patients with diffuse brain gliomas was tested according to the objectives of the study. The QOLIE-31 questionnaire (version 1.0) indicates that diffuse glioma patients with epilepsy have statistically significant decrease in such QOL spheres as seizures worry (p<0.0001), cognitive functioning (p=0.0043), antiepileptic drug effect (p=0.0002), social functioning (p=0.0029), as well as in the total score (p=0.0053). In addition, such factors as age, gender, tumor malignancy degree, and its histological type have a statistically significant effect on the QOL of patients with diffuse brain gliomas before surgery. Thus, the treatment of patients with diffuse brain gliomas requires a thorough study and a multidisciplinary approach, including such specialists as a neurologist, oncologist, chemotherapist, radiologist, neuropsychologist, and psychiatrist, in addition to a neurosurgeon.
- 22 February 2024
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 2,p. 213-224
Quality of life indicators in patients with diffuse brain gliomas
The incidence of primary brain tumors is increasing worldwide. When assessing the treatment delivered to patients with brain gliomas, their quality of life (QOL) is an essential criterion for consideration. It is necessary to search for and specify the factors, which determine the QOL changes in patients with brain tumors. The QOL indicators for patients with brain gliomas were assessed in terms of the following factors: clinical (presence of epileptic seizures, seizures type and frequency, antiepileptic drug treatment, presence of speech disorders and pareses), demographic (sex), age of diagnosis, social (level of education, employment, marital status), molecular-genetic (presence of IDH1/2 mutation, 1p/19q codeletion), and morphological (malignancy degree, tumor histological characteristics). The QOL of 48 patients with diffuse brain gliomas was tested according to the objectives of the study. The QOLIE-31 questionnaire (version 1.0) indicates that diffuse glioma patients with epilepsy have statistically significant decrease in such QOL spheres as seizures worry (p<0.0001), cognitive functioning (p=0.0043), antiepileptic drug effect (p=0.0002), social functioning (p=0.0029), as well as in the total score (p=0.0053). In addition, such factors as age, gender, tumor malignancy degree, and its histological type have a statistically significant effect on the QOL of patients with diffuse brain gliomas before surgery. Thus, the treatment of patients with diffuse brain gliomas requires a thorough study and a multidisciplinary approach, including such specialists as a neurologist, oncologist, chemotherapist, radiologist, neuropsychologist, and psychiatrist, in addition to a neurosurgeon.
- Open Access
- 9 December 2023
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 42 (4) , 337-347
Antiepileptic therapy algorithms in patients with primary and metastatic brain tumors
Up to date the brain tumors incidence keeps growing worldwide. Epilepsy and epileptic seizures are one of the most common clinical features of brain tumors. The aim of the study was to invent the algorithms antiepileptic treatment of patients with primary and metastatic brain tumors based on literature data. We searched eLIBRARY, PubMed databases by keywords. We concluded, that preventive antiepileptic drugs administration in patients with primary or metastatic brain lesions does not lower the risk of acute symptomatic postoperative seizures or epilepsy incidence, and therefore should not be recommended. Experts’ opinion states that in patients with brain tumors even one unprovoked seizure makes it feasible to initiate antiepileptic drugs therapy as soon as possible. In case of two or more unprovoked episodes (with over 24 hours difference) the diagnosis of “epilepsy” is legitimate and antiepileptic therapy should be started. The treating physician’s choice of antiepileptic therapy is based on type of seizures, age and sex of the patient, the comorbidity and potential antiepileptic drugs pharmacokinetic interactions with other drugs (including chemotherapy), in particular, one should avoid the use of liver microsomal-inducing antiepileptic drugs. The presented algorithms provide the decision-making guidelines in case of intraoperative focal seizures, acute symptomatic seizures and status epilepticus occurrence in early postoperative period.
- 9 December 2023
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 42 (4) , 337-347
Open AccessAntiepileptic therapy algorithms in patients with primary and metastatic brain tumors
Up to date the brain tumors incidence keeps growing worldwide. Epilepsy and epileptic seizures are one of the most common clinical features of brain tumors. The aim of the study was to invent the algorithms antiepileptic treatment of patients with primary and metastatic brain tumors based on literature data. We searched eLIBRARY, PubMed databases by keywords. We concluded, that preventive antiepileptic drugs administration in patients with primary or metastatic brain lesions does not lower the risk of acute symptomatic postoperative seizures or epilepsy incidence, and therefore should not be recommended. Experts’ opinion states that in patients with brain tumors even one unprovoked seizure makes it feasible to initiate antiepileptic drugs therapy as soon as possible. In case of two or more unprovoked episodes (with over 24 hours difference) the diagnosis of “epilepsy” is legitimate and antiepileptic therapy should be started. The treating physician’s choice of antiepileptic therapy is based on type of seizures, age and sex of the patient, the comorbidity and potential antiepileptic drugs pharmacokinetic interactions with other drugs (including chemotherapy), in particular, one should avoid the use of liver microsomal-inducing antiepileptic drugs. The presented algorithms provide the decision-making guidelines in case of intraoperative focal seizures, acute symptomatic seizures and status epilepticus occurrence in early postoperative period.
- Open Access
- 17 November 2022
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 41 (4) , 407-413
Acute symptomatic epileptic seizures and epilepsy after stroke
Acute symptomatic epileptic seizures occur within 7 days after the stroke onset. Acute symptomatic epileptic seizures occur in 6.3% of stroke cases: ischemic stroke 4.2%, cerebral infarction with hemorrhagic transformation 12.5%, intracerebral hemorrhage 16.2%. Cumulative risk of subsequent unprovoked epileptic seizure after the first acute symptomatic seizure at follow-up for 10 years is 18.7 %. In acute symptomatic epileptic seizure secondary prevention with antiepileptic drugs usually is not indicated. If antiepileptic drug treatment is initiated after a single acute symptomatic seizure, it should be discontinued after the acute period of the disease. The 10-years risk of subsequent unprovoked epileptic seizures after the single unprovoked epileptic seizure in stroke patients is 71.5%. In this situation the epilepsy diagnosis is reasonable and antiepileptic drug treatment should be initiated. The incidence of epilepsy after acute ischemic or hemorrhagic stroke is identical 1012%. The choice of the group of antiepileptic drugs should be based on clinical guidelines for patients with focal forms of epilepsy. Pharmacokinetic interactions between antiepileptic drugs and oral anticoagulants, antiplatelet agents, antihypertensive drugs, and other xenobiotics should be minimized. Thus antiepileptic drugs that induce or inhibit microsomal liver enzymes should also be avoided.
- 17 November 2022
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 41 (4) , 407-413
Open AccessAcute symptomatic epileptic seizures and epilepsy after stroke
Acute symptomatic epileptic seizures occur within 7 days after the stroke onset. Acute symptomatic epileptic seizures occur in 6.3% of stroke cases: ischemic stroke 4.2%, cerebral infarction with hemorrhagic transformation 12.5%, intracerebral hemorrhage 16.2%. Cumulative risk of subsequent unprovoked epileptic seizure after the first acute symptomatic seizure at follow-up for 10 years is 18.7 %. In acute symptomatic epileptic seizure secondary prevention with antiepileptic drugs usually is not indicated. If antiepileptic drug treatment is initiated after a single acute symptomatic seizure, it should be discontinued after the acute period of the disease. The 10-years risk of subsequent unprovoked epileptic seizures after the single unprovoked epileptic seizure in stroke patients is 71.5%. In this situation the epilepsy diagnosis is reasonable and antiepileptic drug treatment should be initiated. The incidence of epilepsy after acute ischemic or hemorrhagic stroke is identical 1012%. The choice of the group of antiepileptic drugs should be based on clinical guidelines for patients with focal forms of epilepsy. Pharmacokinetic interactions between antiepileptic drugs and oral anticoagulants, antiplatelet agents, antihypertensive drugs, and other xenobiotics should be minimized. Thus antiepileptic drugs that induce or inhibit microsomal liver enzymes should also be avoided.
- Open Access
- 27 July 2022
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 14 (2) , 204-213
The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
- 27 July 2022
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 14 (2) , 204-213
Open AccessThe role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas
- Open Access
- 6 December 2021
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 40 (4) , 59-68
Epileptic status: reality 2021
Epileptic status is one of the urgent conditions in neurology that requires clear and urgent measures at any stage of medical care. It ranks second among all urgent neurological conditions. The therapeutic principle time-brain is applicable not only for urgent measures in acute cerebrovascular accident, but also for the relief of epileptic status, since the worst prognosis is associated with an increase in the duration of seizure activity. According to the standards proposed in the world for the treatment of epileptic status, benzodiazepines, intravenous forms of antiepileptic drugs, and general anesthetics are used. In the Russian Federation, the use of many drugs is limited due to the lack of registration, their lack in standards, and unavailability in hospitals. Due to the lack of studies on the treatment of epileptic status that go beyond the early stage of status, most of the recommendations presented worldwide remain based on case series or expert judgment. The efficacy benefits of anti-status drugs used in the second and third stages of epileptic status therapy remain unclear. Therefore, if there is a choice of anti-status drugs, the decision of which drug, in what dose and in what sequence will be used, should be made by the senior and most trained doctor in this matter, taking into account the characteristics of each patient. Based on modern international and personal experience, the paper presents a step-by-step protocol for the treatment of generalized convulsive epileptic status, discusses the successes and problems of providing care to patients with this pathology in Russia. The quality of medical care in epileptic status can be significantly improved provided that medical personnel at all stages of the treatment protocol are required to evacuate patients with epileptic status to specialized centers of multidisciplinary hospitals with the possibility of examination and therapy, including the availability of EEG monitors, neuroimaging and laboratory capabilities, and also access to modern antiepileptic drugs (1 table, bibliography: 30 refs)
- 6 December 2021
- Published by ECO-Vector LLC in Russian Military Medical Academy Reports
- Vol. 40 (4) , 59-68
Open AccessEpileptic status: reality 2021
Epileptic status is one of the urgent conditions in neurology that requires clear and urgent measures at any stage of medical care. It ranks second among all urgent neurological conditions. The therapeutic principle time-brain is applicable not only for urgent measures in acute cerebrovascular accident, but also for the relief of epileptic status, since the worst prognosis is associated with an increase in the duration of seizure activity. According to the standards proposed in the world for the treatment of epileptic status, benzodiazepines, intravenous forms of antiepileptic drugs, and general anesthetics are used. In the Russian Federation, the use of many drugs is limited due to the lack of registration, their lack in standards, and unavailability in hospitals. Due to the lack of studies on the treatment of epileptic status that go beyond the early stage of status, most of the recommendations presented worldwide remain based on case series or expert judgment. The efficacy benefits of anti-status drugs used in the second and third stages of epileptic status therapy remain unclear. Therefore, if there is a choice of anti-status drugs, the decision of which drug, in what dose and in what sequence will be used, should be made by the senior and most trained doctor in this matter, taking into account the characteristics of each patient. Based on modern international and personal experience, the paper presents a step-by-step protocol for the treatment of generalized convulsive epileptic status, discusses the successes and problems of providing care to patients with this pathology in Russia. The quality of medical care in epileptic status can be significantly improved provided that medical personnel at all stages of the treatment protocol are required to evacuate patients with epileptic status to specialized centers of multidisciplinary hospitals with the possibility of examination and therapy, including the availability of EEG monitors, neuroimaging and laboratory capabilities, and also access to modern antiepileptic drugs (1 table, bibliography: 30 refs)